Bausch Health Companies Inc. Stock 12‑Month Price Target Raised to $7.72, Implies 12% Upside

Analysts raised Bausch Health's 12-month price target to $7.72, up from $7.54, implying 12% upside. The consensus rating remains 'Hold' with 1 Buy, 5 Holds, and 0 Sells. The forecasts range from $6.51 to $10.03 per share, according to 5 analysts.

Original reporting
Published Oct 29, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bausch Health Companies Inc. Stock 12‑Month Price Target Raised to $7.72, Implies 12% Upside — source image
Decision brief

The 30-second read

$BHCBullishLow
01

Why it matters

Analyst upgrades typically generate short‑term buying interest, but the magnitude is modest given the small absolute price level.

02

Market read

The update offers a small upside catalyst for BHC but is unlikely to move broader markets.

03

What to watch

Potential downside from pending regulatory or litigation risks not reflected in the new target.

Relevance 5/10Novelty 5/10Timing: today

Background

Bausch Health Companies Inc. (NYSE:BHC) is a specialty pharmaceutical firm. The article reports a fresh analyst consensus price‑target increase.

Company-level read

Ticker impact

$BHCBullishMedium confidence
Context

Analyst consensus price target raised to $7.72, implying ~12% upside versus the Oct. 28 close.

Expected impact

likely modest upside as the market incorporates the higher target

Evidence & confidence

Price‑target upgrades are a forward‑looking signal; the change is modest and reflects incremental optimism.

Market effects

Minor impact on the healthcare sector as Bausch Health is a small‑cap pharma player.

Limited to North American markets where the stock trades.

Low; the story does not affect broader market indices.

Counterpoint

The target raise may be premature if underlying earnings guidance remains unchanged.

Key entities

  • Bausch Health Companies Inc.

    Specialty pharma company whose price target was raised.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.